Novel Uses For Oral Solid Doses Driving Lifecycle Management Strategies

Source: Thermo Fisher Scientific

By Anil Kane, Ph.D.

Novel Uses for Oral Solid Doses Driving Lifecycle Management Strategies

With few potential blockbuster drugs in the pharma pipeline right now, drug companies are increasingly looking at other options to meet the needs of patients and increase revenue in the oral solid dosage (OSD) arena. Current areas of exploration include novel drug combinations, oral delivery of large molecules that were available only as injectables, and perhaps most interesting, drugs that carry digital, ingestible sensors that can send information directly to a physician.

“The new drug pipeline is shrinking,” says Anil Kane, PhD, Global Head of Technical and Scientific Affairs at Patheon, part of Thermo Fisher Scientific, a leading contract development and manufacturing organization. “So many companies are looking to expand their product portfolio from their existing molecules. They are looking into many different lifecycle management strategies.”

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online